Nalufenya Childrens
Jinja, Uganda
Location status: Recruiting
Location contact
Emmanuel Tenywa
CONTACT
Nelson Sewankambo
PRINCIPAL_INVESTIGATOR
Ruth Namazzi
SUB_INVESTIGATOR
NCT Number: NCT07610239
A cluster randomized trial (CRT) of the novel sickle cell disease (SCD), M-health based SCD Information Management and Communication system SIMCS vs routine new born screening strategy in health care centres in Uganda to evaluate impact on access screening, coordination of care and clinical outcomes
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Jinja, Uganda
Location status: Recruiting
Emmanuel Tenywa
CONTACT
Nelson Sewankambo
PRINCIPAL_INVESTIGATOR
Ruth Namazzi
SUB_INVESTIGATOR
We will conduct a cluster randomized trial (CRT) of the novel SCD SIMCS and utilize a logical framework of measurable indicators of barriers, utilization, mediating factors, and clinical outcomes of SCD screening and care to evaluate its impact. We will randomize health facilities rather than individual patients because it would be impossible to avoid contamination if we randomized individuals. This design is ideal for evaluating the effectiveness of systems level interventions.
Study procedures Trial Intervention. SCD SIMCS APP, which is an AI-enhanced mobile platform that captures, interprets and relays results of point of care tests for SCD to health care providers and to a centralised public data server at the Uganda Ministry of Health. The SCD SIMCS app prototype consists of four modules: (1) ID module - captures child's demographic and biometric data and builds a printable QR-code; (2) Assay module - captures HemoTypeSCTM and the Sickle Scan TM test image, interprets, and transmits results to the CPHL data centre; (3) Education module - stores and plays back short educational videos for pre- and post-screening counselling; (4) SCD e-Passport module - entry and display of child's longitudinal salient clinical information.
Baseline assessment; following stratified purposive sampling and consent from community leaders, Control and Experimental HCs will undergo baseline evaluation with regards to current resources and childcare visit workflows and the availability of the data sources and measurable indicators of interest. A baseline assessment of resources, workflows, and routine source data collection systems at the centres will facilitate implementation planning for the proposed SCD SIMCS and accurate measurement of its impact on the HCs.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Providers of child health and maternity services at selected hospitals Infants born or attending child health and maternity services at selected hospitals . Infants are the targeted age-group in this study because this is the ideal age to screen for SCD and prevent complications and mortality that generally occurs early, by 5 years old. The infants will be recruited at birth or at vaccination visits
Exclusion criteria
Mobile Health information managment system
Time frame: 12 months
proportion with positive sickle cell disease screen recievign conformatory SCD test,penicillin , hydroxyurea
Time frame: 18 months
Evaluate the impact of the SCD SIMCS on access to screening.
Contact information is provided by the study sponsor or research team.
Makerere University
Other
Acronym: SMICS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07187973
Anemia, Anemia, Hemolytic
Birmingham, Alabama, United States
View Trial DetailsNCT00542230
Anemia, Anemia, Hemolytic
Bethesda, Maryland, United States
View Trial DetailsNCT03937817
Alpha and Beta Thalassemia, Anemia
Bethesda, Maryland, United States
View Trial DetailsNCT02675959
Anemia, Anemia, Hemolytic
Los Angeles, California, United States
View Trial Details